Alemtuzumab is under clinical development by Sanofi and currently in Phase I for T-Cell Leukemia. According to GlobalData, Phase I drugs for T-Cell Leukemia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Alemtuzumab LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Alemtuzumab overview
Alemtuzumab (MabCampath, Campath,) is a CD52-directed cytolytic humanized monoclonal antibody directed against lymphocytes through the CD-52 receptor. It is formulated as injectable concentrated solution for intravenous route administration. Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) and T-cell leukemia. MabCampath is indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia
The drug candidate is under development for the treatment of T-cell leukemia. It was under development relapsed or refractory mycosis fungoides, sezary syndrome, graft versus host disease, peripheral T-cell lymphomas, hematological disorders, B-cell chronic lymphocytic leukemia as second line therapy, diffuse large B-cell lymphoma, follicular lymphomA, lymphoproliferative disorders as second line therapy and T-cell prolymphocytic leukemia.
Sanofi overview
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi’s R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has an operational presence in Europe, the Americas, Africa, Asia-Pacific, and the Middle East. Sanofi is headquartered in Paris, Ile-de-France, France.
For a complete picture of Alemtuzumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
